Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy

Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.

Related Keywords

Germany ,Bochum ,Nordrhein Westfalen ,Salt Lake City ,Utah ,United States ,John Foley ,Kerstin Hellwig ,Commitment To Health ,Department Of Neurology ,European Medicines Agency ,Rocky Mountain ,Medscape Medical News ,Tysabri Outreach ,Unified Commitment ,Product Characteristics ,Catholic Clinic Bochum ,Multiple Sclerosis Ms ,Multiple Sclerosis ,Us ,Progressive Multifocal Leukodystrophy ,Progressive Multifocal Leukoencephalopathy ,Multiple Sclerosis Relapse ,S Relapse ,Elapse Of Multiple Sclerosis ,Elapse Of Ms ,Relapsing Remitting Multiple Sclerosis ,Arms ,Ultiple Sclerosis Relapsing Remitting ,Multiple Sclerosis Treatment ,Als Treatment ,Reatment Of Multiple Sclerosis ,Reatment Of Ms ,Magnet ,